Corcept Therapeutics INC 8-K filings

Corcept Therapeutics reports strong Q2 2026 results with revenue up 32% to $256.1 million, driven by Korlym and the new Lifyorli, and raises full-year revenue guidance.

Corcept Therapeutics has resubmitted its New Drug Application to the FDA for relacorilant to treat Cushing's syndrome, following FDA requests for additional data analysis.

Corcept Therapeutics announced the U.S. Department of Justice will not intervene in a civil lawsuit filed by a former employee.

Corcept Therapeutics stockholders approved an 8 million share increase to the 2024 Incentive Award Plan and re-elected all eight board directors.

Corcept Therapeutics reported Q1 2026 revenue of $164.9 million and raised its full-year revenue guidance to $950-$1,050 million following the FDA approval of Lifyorli.

Corcept Therapeutics announced FDA approval of Lifyorli (relacorilant) in combination with nab-paclitaxel for platinum-resistant ovarian cancer.

Corcept Therapeutics announced full-year 2025 revenue of $761.4 million, provided 2026 revenue guidance, and detailed significant progress across its clinical development programs.

Corcept Therapeutics announced a federal appeals court ruled Teva Pharmaceuticals' generic Korlym does not infringe two of its co-administration patents.

Corcept Therapeutics announced its pivotal Phase 3 ROSELLA trial for relacorilant in platinum-resistant ovarian cancer met its overall survival primary endpoint, showing a 35% reduction in death risk.

Corcept Therapeutics received a Complete Response Letter from the FDA for relacorilant as a treatment for hypertension secondary to hypercortisolism, citing a need for additional effectiveness evidence.

Corcept Therapeutics announced third-quarter 2025 financial results with revenue growth and expanded oncology development programs, alongside modified full-year guidance.

Corcept Therapeutics has terminated its distribution services agreement with Optime Care, effective January 8, 2026, for its Korlym and generic mifepristone medications.

Corcept Therapeutics announced the resignation of Dr. Gillian Cannon from its Board of Directors, effective October 10, 2025, with her transitioning to a consulting role.

The FDA has accepted Corcept Therapeutics' New Drug Application for relacorilant as a treatment for platinum-resistant ovarian cancer, setting a PDUFA date of July 11, 2026.

Corcept Therapeutics announced second quarter 2025 financial results with revenue growth but declining net income, while advancing multiple clinical programs and modifying its full-year revenue guidance due to pharmacy capacity constraints.

Corcept Therapeutics has submitted a New Drug Application to the U.S. Food and Drug Administration for its proprietary drug, relacorilant, to treat patients with platinum-resistant ovarian cancer, building on positive Phase 3 and Phase 2 trial data.

Corcept Therapeutics Incorporated announced the successful passage of all three proposals at its 2025 annual meeting of stockholders, including the re-election of nine directors, ratification of Ernst & Young LLP as auditor, and advisory approval of executive compensation.

Corcept Therapeutics reports Q1 2025 revenue of $157.2 million, reiterates 2025 revenue guidance of $900-$950 million, and progresses clinical development programs.

Corcept Therapeutics announces positive Phase 3 ROSELLA trial results for relacorilant plus nab-paclitaxel in platinum-resistant ovarian cancer, demonstrating improved progression-free survival.

The FDA has filed Corcept Therapeutics' New Drug Application for relacorilant, a selective cortisol modulator, for the treatment of endogenous hypercortisolism (Cushing's syndrome).

Corcept Therapeutics announces strong 2024 financial results with a 40% revenue increase and provides promising revenue guidance for 2025, while also highlighting progress in its clinical development programs.

Corcept Therapeutics has submitted a new drug application to the FDA for relacorilant, a selective cortisol modulator, to treat patients with endogenous hypercortisolism (Cushing's syndrome).

Corcept Therapeutics announced a 48% year-over-year revenue increase in Q3 2024, positive results from the Phase 3 GRADIENT trial for Cushing's syndrome, and raised its full-year revenue guidance.

Corcept Therapeutics announced a 39% increase in revenue for the second quarter of 2024, along with an increase to their full-year revenue guidance.

Corcept Therapeutics held its 2024 Annual Meeting where stockholders approved a new incentive plan, elected directors, and ratified the appointment of Ernst & Young as their auditor.

Corcept Therapeutics announced a 39 percent increase in revenue for the first quarter of 2024, along with an increase to their full-year revenue guidance.

Corcept Therapeutics has entered into a sublease agreement for additional office space in Redwood City, California, commencing in July 2024.

Corcept Therapeutics announced a 31% increase in fourth-quarter revenue and a 20% increase in full-year revenue for 2023, along with a reiteration of their 2024 revenue guidance.